{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:52:24Z","timestamp":1773294744819,"version":"3.50.1"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2624,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Introduction:<\/jats:bold> Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was an 8-week, open-label, prospective study of aripiprazole 9.4\u00b14.2 mg\/day monotherapy to assess the efficacy and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale, Clinical Global Impressions-Improvement scale, and Brief Psychiatric Rating Scale. Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Fifteen of the 19 bipolar youth (79%) completed the study. Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (\u221218.0\u00b16.9, <jats:italic>P<\/jats:italic>&lt;.0001). With the important exception of two cases of extrapyramidal symptoms that precipitated dropout, aripiprazole was well tolerated with no statistically significant increase in body weight (1.8\u00b11.7 kg, <jats:italic>P<\/jats:italic>=.2).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder. Future placebo-controlled, double blind studies are warranted.<\/jats:p>","DOI":"10.1017\/s1092852900021519","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:55:56Z","timestamp":1470099356000},"page":"683-689","source":"Crossref","is-referenced-by-count":53,"title":["An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder"],"prefix":"10.1017","volume":"12","author":[{"given":"Joseph","family":"Biederman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagan","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hammerness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Kotarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Aleardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900021519_ref023","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199510000-00014"},{"key":"S1092852900021519_ref020","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199507000-00010"},{"key":"S1092852900021519_ref014","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S1092852900021519_ref013","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199203000-00011"},{"key":"S1092852900021519_ref011","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S1092852900021519_ref010","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280119e0c"},{"key":"S1092852900021519_ref018","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"S1092852900021519_ref009","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.593"},{"key":"S1092852900021519_ref008","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900019489"},{"key":"S1092852900021519_ref007","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000194567.63289.97"},{"key":"S1092852900021519_ref002","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"S1092852900021519_ref001","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1263"},{"key":"S1092852900021519_ref012","doi-asserted-by":"publisher","DOI":"10.3109\/10401239509149039"},{"key":"S1092852900021519_ref005","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.311"},{"key":"S1092852900021519_ref016","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.13.3.384"},{"key":"S1092852900021519_ref017","first-page":"839","article-title":"CGI (Clinical Global Impression) Scale","volume":"21","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900021519_ref015","doi-asserted-by":"publisher","DOI":"10.1207\/S15374424JCCP3104_15"},{"key":"S1092852900021519_ref019","first-page":"249","article-title":"Risperidone in the treatment of mania","volume":"57","author":"Tohen","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852900021519_ref004","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595568"},{"key":"S1092852900021519_ref006","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.019"},{"key":"S1092852900021519_ref021","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199705000-00021"},{"key":"S1092852900021519_ref022","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199705000-00020"},{"key":"S1092852900021519_ref003","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0401"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900021519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T17:00:42Z","timestamp":1556730042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900021519\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1092852900021519"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900021519","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}